Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in revenue from its weight loss and obesity drugs Mounjaro and ...

And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro and ...

The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and Saxenda for weight loss. Because Eli Lilly's tirzepatide did not hit the market as Mounjaro for diabetes ...

Let's look at five pharma and drug companies ... by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus. Here's why they view Eli Lilly (NYSE: LLY), Novo ...

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity drugs. The pharma group ...

Eli Lilly has launched a new website-based ... but it also covers diabetes and migraine drugs, respectively, via telehealth providers 9amHealth and Cove. According to the company, it allows ...

1,2 The Egyptian Drug Authority approved the insulin ... Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion ...